Welcome to our dedicated page for Sonendo news (Ticker: SONX), a resource for investors and traders seeking the latest updates and insights on Sonendo stock.
Sonendo, Inc. reports developments as a commercial-stage dental technology company built around the GentleWave® System for root canal therapy. The company develops and manufactures a platform that uses procedure fluid optimization, broad-spectrum acoustic energy and fluid dynamics to clean and disinfect microscopic spaces within teeth while preserving tooth structure.
SONX news commonly covers quarterly and annual results, console sales, procedure-related consumables and service revenue, gross margin, operating expense reductions and cash-flow guidance. Company updates also address commercial execution, liquidity actions such as private placements and credit facility amendments, leadership changes, and the completed divestiture of the TDO practice management software segment.
Sonendo, Inc. (OTCQX: SONX), a dental technology company, has entered into an Asset Purchase Agreement to acquire substantially all assets of Biolase, Inc. and its subsidiaries for $14 million, plus assumption of certain liabilities and settlement of ongoing patent litigation. Biolase filed for Chapter 11 bankruptcy on October 1, 2024. Sonendo will be designated as the "stalking horse" bidder in a Bankruptcy Court-supervised process, subject to higher offers and court approval.
Sonendo's CEO, Bjarne Bergheim, expressed commitment to ensuring a smooth transition for Biolase customers, patients, suppliers, and vendors. The company anticipates cross-selling opportunities and cost reduction synergies as a combined entity. In January 2023, Sonendo's subsidiary, PIPStek , filed a patent infringement lawsuit against Biolase, claiming damages of not less than $59,000,000.
Sonendo, Inc. (OTCQX: SONX) reported its Q2 2024 financial results, showing promising signs of recovery. The company generated $8.3 million in total revenue, a slight 5% decrease from Q2 2023. However, GentleWave console revenue increased by 9% to $2.4 million. Notably, GAAP gross margin improved significantly to 37.5% from a negative 5.5% in Q2 2023, while adjusted gross margin reached 40.7%. The company also reduced its GAAP operating loss by 61% to $6.7 million and its adjusted EBITDA loss by 55% to $5.7 million. Based on these improvements, Sonendo has raised its 2024 full-year revenue guidance to $31-$32 million, up from the previous $29-$31 million range.
Sonendo, a dental technology company, will report its second quarter 2024 financial results on August 7, 2024, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day to discuss the results.
Interested investors can join the call by dialing (833) 470-1428 (domestic) or (404) 975-4839 (international) with the access code 699662. Live audio and an archived recording of the webcast will be available on the company's investor relations website, with the replay accessible for at least 30 days post-event.
Sonendo (OTCQX: SONX), a dental technology company known for its GentleWave® System, has announced key leadership changes. John Bostjancic has been appointed as Chief Financial Officer, Robert Guyatt as Senior Vice President of Marketing, and John McGaugh has been promoted to Senior Vice President of Operations. CEO Bjarne Bergheim stated that these appointments are part of a 'reset strategy' aimed at enhancing commercial execution, margin expansion, and cash conservation. These leadership changes are expected to drive significant growth and operational improvements for Sonendo.
Sonendo, a prominent dental technology company and creator of the GentleWave® System, will participate in the 2024 Stifel Jaws & Paws Conference. This event is scheduled for May 29th, with Sonendo's management presenting at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time. Investors and interested parties can access an audio webcast of the presentation through the company's website. This participation underscores Sonendo's commitment to engaging with the investor community and showcasing its innovative dental solutions.
Sonendo, Inc. reported total revenue of $7.0 million for Q1 2024, surpassing guidance. They achieved a healthy console backlog, raised average procedure instrument selling price, and divested TDO software segment. The company announced a strategic reset focusing on commercial strategy, cash conservation, and margin expansion. Despite a GAAP operating loss of $10.2 million, non-GAAP operating loss improved. Sonendo raised their 2024 revenue guidance range to $29-$31 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.